Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model

BACKGROUND: Dolutegravir (DTG) is a recommended first-line regimen for all people with Human Immunodeficiency Virus (HIV) infection. Initial findings from Botswana, a country with no folate fortification program, showed an elevated prevalence of neural tube defects (NTDs) with peri-conceptional expo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Haneesha, Nguyen, Jessica, MacKenzie, Ben, Yee, Audrey, Laurette, Evelyn Yukino, Sanghvi, Tanvi, Tejada, Oscar, Dontsova, Valeriya, Leung, Kit-Yi, Goddard, Cameron, De Young, Taylor, Sled, John G., Greene, Nicholas D.E., Copp, Andrew J., Serghides, Lena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450420/
https://www.ncbi.nlm.nih.gov/pubmed/37586112
http://dx.doi.org/10.1016/j.ebiom.2023.104762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450420/
https://www.ncbi.nlm.nih.gov/pubmed/37586112
http://dx.doi.org/10.1016/j.ebiom.2023.104762

Ejemplares similares